1. Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry 
Jens Garbade, MD, PhD, Finn Gustafsson, MD, PhD, Steven Shaw, MD, PhD, Jacob Lavee, MD, Diyar Saeed, MD, PhD, Yuriy Pya, MD, Thomas Krabatsch, MD, PhD, Jan D. Schmitto, MD, PhD, Michiel Morshuis, MD, Joyce Chuang, PhD, Daniel Zimpfer, MD, PhD 
The Annals of Thoracic Surgery 
Volume 107, Issue 1, Pages (January 2019)
DOI: /j.athoracsur
Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Breakdown of groups for analysis of the ELEVATE registry. (ELEVATE = Evaluating the HeartMate 3 with Full MagLev Technology in a Post-Market Approval Setting; HM3 = HeartMate 3; LVAD = left ventricular assist device.)
The Annals of Thoracic Surgery  , 33-39DOI: ( /j.athoracsur )
Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
(A) Thirty-day survival of all ELEVATE registry patients including 58 anonymized patients and 19 patients receiving the HeartMate 3 (Abbott, Chicago, IL) as a replacement for another pump. (B) Thirty-day survival of the ELEVATE registry primary implant and European Conformity Mark (CE Mark [CEM]) groups. The hazard ratio (HR) for ELEVATE registry versus CE Mark trial is adjusted for baseline differences in age, INTERMACS profile, low hematocrit, and concomitant valve procedures. (ELEVATE = Evaluating the HeartMate 3 with Full MagLev Technology in a Post-Market Approval Setting; INTERMACS = Interagency Registry for Mechanically Assisted Circulatory Support.)
The Annals of Thoracic Surgery  , 33-39DOI: ( /j.athoracsur )
Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions